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Optimising influenza vaccination 
during a SARS-CoV-2 epidemic in 
South Africa could help maintain the 
integrity of our healthcare system
To the Editor: The novel infectious disease coronavirus disease 
2019 (COVID-19), first reported in late December 2019 in Wuhan, 
China, seems increasingly unlikely to be contained, resulting in the 
first pandemic of this decade. Approximately 81% of those infected 
develop a relatively mild respiratory illness only. While this is good 
news, the risk of severe disease is higher for the elderly and persons 
with chronic illness.
The cause of COVID-19 is a virus newly seen in humans, severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As it 
spreads globally through a population that lacks any (even partial) 
immunity from vaccination or past infection, it will cause a ‘virgin 
soil’ epidemic. Even with a relatively low case fatality rate, the sheer 
number of potential infections may give rise to significant morbidity 
and mortality and may overwhelm already strained healthcare 
systems.
As the pandemic spreads and has now been declared officially, the 
goal of public health measures will be to spread out the epidemic 
curve: the flatter and broader it becomes, the less acute the burden 
on the healthcare system. If the first epidemic wave of COVID-19 
coincides with the influenza season, it will cause an even higher peak 
in seasonal respiratory tract infections and hospital admissions, and 
push healthcare systems to breaking point.
In order to maintain the integrity of South Africa (SA)’s healthcare 
system at a time that is likely to coincide with our winter influenza 
season, one important measure will be to optimise influenza 
vaccination of healthcare workers and high-risk patients to reduce 
the likelihood of a ‘double hit’. Adults in high-risk groups for invasive 
pneumococcal disease, such as those with HIV and other causes of 
immunosuppression, should also receive pneumococcal conjugate 
vaccine. While the influenza vaccine is not perfect, it reduces 
the risk of infection and severe influenza illness. Fewer patients 
with respiratory complaints and more healthy staff at work would 
be of great benefit if SARS-CoV-2 and seasonal influenza strike 
simultaneously. In addition, vaccinees are less likely to be flagged 
as potential COVID-19 cases, decreasing the need for isolation 
and laboratory testing. While (as always) there will not be enough 
influenza vaccine doses available in SA to cover all groups for which 
vaccination is recommended, the harsh reality is that even this 
limited supply tends not to be used in its entirety.
Reducing morbidity and mortality through better influenza 
vaccination uptake might be one good thing to come out of this new 
public health threat, and help the country maintain the integrity of 
its healthcare system.
Wolfgang Preiser
Division of Medical Virology, Department of Pathology, Faculty of 
Medicine and Health Sciences, Stellenbosch University, Cape Town, 
South Africa; and National Health Laboratory Service, Tygerberg 
Hospital, Cape Town, South Africa
preiser@sun.ac.za
Marc Mendelson
Division of Infectious Diseases and HIV Medicine, Department of 
Medicine, Faculty of Health Sciences, University of Cape Town and 
Groote Schuur Hospital, Cape Town, South Africa
Jantjie Taljaard
Division of Adult Infectious Diseases, Department of Medicine, 
Faculty of Medicine and Health Sciences, Stellenbosch University and 
Tygerberg Hospital, Cape Town, South Africa
S Afr Med J 2020;110(4):259. https://doi.org/10.7196/SAMJ.2020.v110i4.14692
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
